Eur J Heart Fail: The effect of dapagliflozin on anemia in heart failure patients with reduced ejection fraction

Anemia is common in patients with heart failure (HF), which is very complex etiology, it may reflect renal dysfunction, inflammation, iron deficiency and use of vascular angiotensin-converting enzyme inhibitor therapy .

Anemia is common in patients with heart failure (HF), which is very complex etiology, it may reflect renal dysfunction, inflammation, iron deficiency and use of vascular angiotensin-converting enzyme inhibitors and other treatment of vascular heart failure

Docherty et al.

Analyzed the effect of dapagliflozin on correcting anemia in HF patients with reduced ejection fraction

Anemia is defined as a hematocrit of <39% in men and 36% in women at baseline.

medsci.

The effect of dapagliflozin on cardiovascular prognosis in HF patients with or without anemia

The effect of dapagliflozin on cardiovascular prognosis in HF patients with or without anemia

The incidence of the main outcome of anemia patients (16.

The incidence of the main outcome of anemia patients (16.

The effect of dapagliflozin on patients' hematocrit

The effect of dapagliflozin on patients' hematocrit

Compared with non-anemic patients, the effect of dapagliflozin on the main prognosis is consistent [hazard ratio (HR) 0.

In conclusion, in the DAPA-HF trial, the prognosis of HF patients with anemia was poor .

HF patients with anemia of poor prognosis and poor prognosis in patients with anemia of HF dapagliflozin treatment increases the rate of anemia correction in patients and improve the prognosis of patients with dapagliflozin treatment increases the rate of anemia correction in patients, and Improved patient prognosis

Original source:

Original source:

Docherty Kieran F, Curtain James P, Anand Inder S et al.

org/10.
1002/ejhf.
2132" target="_blank" rel="noopener">Effect of dapagliflozin on anaemia in DAPA- HF in this message